Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anna Maria Litvak"'
Autor:
Marc Ladanyi, Wei-Chu Lai, Ai Ni, David S. Klimstra, Isabel Ruth Preeshagul, Anna Maria Litvak, Jason C. Chang, Maria Lauren Santos-Zabala, Charles M. Rudin, M.C. Pietanza, Natasha Rekhtman, Patrice Desmeules, Joseph Montecalvo, Amanda Beras, William D. Travis, Joshua K. Sabari
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
The spectrum and evolution of proliferation rates in stage IV lung carcinoids is poorly defined. In particular, there are limited data on the prevalence and characteristics of tumors exceeding the standard upper proliferative criteria—as defined la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c467aa8ab30d71aea755ee33f0d63ba
https://doi.org/10.1038/s41379-019-0248-2
https://doi.org/10.1038/s41379-019-0248-2
Autor:
Ai Ni, Maureen Kennedy, Anne Haughney-Siller, Linda Ahn, Gregory J. Riely, Elizabeth Panora, Adam J. Schoenfeld, Natasha Rekhtman, Anna Maria Litvak, Marc Ladanyi, Mark G. Kris, Helena A. Yu, Michelle S. Ginsberg, Maria E. Arcila, Kathryn C. Arbour, Vincent A. Miller, Alexander Drilon, Joseph Montecalvo
Publikováno v:
Cold Spring Harbor Molecular Case Studies
KRAS G12D-mutant/p53-deficient non-small-cell lung cancer (NSCLC) models are dependent on the NF-κB pathway that can be down-regulated by the proteasome inhibitor bortezomib. Two exceptional responders were observed on prior clinical trials of borte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07c99b178b4c4f384ed0c1c5254afdd1
http://europepmc.org/articles/PMC6549573
http://europepmc.org/articles/PMC6549573
Autor:
Natasha Rekhtman, Paul K. Paik, Maria Catherine Pietanza, Alexander Drilon, Anna Maria Litvak, Jamie E. Chaft, Gregory J. Riely, Kaitlin M. Woo, Mark G. Kris
Publikováno v:
Journal of Clinical Oncology. 33:e19002-e19002
e19002 Background: KRAS mutations are the most common oncogenic drivers in lung cancers without any approved targeted therapy. Preclinical evidence suggests that KRAS mutations are highly dependent...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaf71da898979d12f14941b572fadbbd
https://doi.org/10.1200/jco.2015.33.15_suppl.e19002
https://doi.org/10.1200/jco.2015.33.15_suppl.e19002
Autor:
Sara A. Hayes, Maria Teresa Ruiz Tsukazan, Gregory J. Riely, Andre L. Moreira, James Huang, Camelia S. Sima, Anna Maria Litvak, Kaitlin M. Woo
Publikováno v:
Journal of Clinical Oncology. 32:7603-7603
7603 Background: Thymic carcinomas (TC) are rare cancers with limited data regarding outcomes, particularly for those patients (pts) with advanced disease. Methods: We identified pts with TC diagno...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad8792eacaa707252cf34a8a5019289d
https://doi.org/10.1200/jco.2014.32.15_suppl.7603
https://doi.org/10.1200/jco.2014.32.15_suppl.7603
Autor:
Anne Haughney-Siller, Melanie Albano, Lee M. Krug, Anna Maria Litvak, Martin Fleisher, Dorothy Dulko, Anna M. Varghese, Andrei I. Holodny, Mark G. Kris, Grace Monger, Payal R. Patel, Camelia S. Sima, Kenneth K.-S. Ng, Jerrold B. Teitcher, Clare M Moran, Maria Catherine Pietanza, Charles M. Rudin, Fawzia Ibrahim
Publikováno v:
Journal of Clinical Oncology. 32:7602-7602
7602 Background: SCLC relies on the Hh developmental pathway for tumor initiation and progression. Pharmacologic blockade with Hh inhibitors blocks these processes. We performed a phase I study to ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e12ca9ee27b8a673b4e08191dfc72372
https://doi.org/10.1200/jco.2014.32.15_suppl.7602
https://doi.org/10.1200/jco.2014.32.15_suppl.7602